ResMed (ASX:RMD) is still batting eyelashes at brokers, with Ord Minnett reaffirming its “Buy” rating following what it called a “solid” quarterly performance. Listen to the HotCopper podcast for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback